Growth Metrics

Bio-Techne (TECH) Gross Margin (2009 - 2026)

Bio-Techne's quarterly Gross Margin came in at 66.88% in Q1 2026, down 97.0% year-on-year from 2229.48% in Q1 2025, and up 3.46% quarter-over-quarter from 64.65% in Q4 2025.

Bio-Techne has reported Gross Margin for 18 years, with the latest figure at 66.88% in Q1 2026.

  • For the quarter ending Q1 2026, Gross Margin fell 97.0% year-over-year to 66.88%; the trailing twelve-month figure through Mar 2026 stood at 64.96% (down 80.0% YoY), and the FY2025 full-year result was 64.8%, down 161.0% from the prior year.
  • Gross Margin for Q1 2026 stood at 66.88%, up from 64.65% in the prior quarter.
  • The five-year high for Gross Margin was 8979.75% in Q3 2022, with the low at 62.72% in Q2 2025.
  • Average Gross Margin over 5 years is 590.86%, with a median of 66.88% recorded in 2026.
  • Year-over-year, Gross Margin soared 891340 bps in 2022 and slumped 891288 bps in 2023.
  • Tracing TECH's Gross Margin over 5 years: stood at 67.52% in 2022, then retreated by 4 bps to 64.78% in 2023, then advanced by 1 bps to 65.27% in 2024, then retreated by 1 bps to 64.65% in 2025, then climbed by 3 bps to 66.88% in 2026.
  • The last three Gross Margin figures came in at 66.88% (Q1 2026), 64.65% (Q4 2025), and 65.65% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 Bio-Techne 7.92 Bn 7.71 Bn 208.29 Mn 66.88%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 66.88%
Dec 31, 2025 64.65%
Sep 30, 2025 65.65%
Jun 30, 2025 62.72%
Mar 31, 2025 67.86%
Dec 31, 2024 65.27%
Sep 30, 2024 63.23%
Jun 30, 2024 66.43%
Mar 31, 2024 67.43%
Dec 31, 2023 64.78%
Sep 30, 2023 66.87%
Jun 30, 2023 67.93%
Mar 31, 2023 68.73%
Dec 31, 2022 67.52%
Sep 30, 2022 8,979.75%
Jun 30, 2022 69.51%
Mar 31, 2022 69.38%
Dec 31, 2021 68.22%
Sep 30, 2021 66.35%
Jun 30, 2021 67.92%
Mar 31, 2021 69.09%
Dec 31, 2020 67.29%
Sep 30, 2020 67.45%
Jun 30, 2020 64.44%
Mar 31, 2020 66.81%
Dec 31, 2019 65.65%
Sep 30, 2019 64.62%
Jun 30, 2019 66.92%
Mar 31, 2019 67.41%
Dec 31, 2018 64.76%
Sep 30, 2018 66.03%
Jun 30, 2018 67.78%
Mar 31, 2018 67.24%
Dec 31, 2017 66.06%
Sep 30, 2017 67.68%
Jun 30, 2017 65.38%
Mar 31, 2017 67.12%
Dec 31, 2016 66.87%
Sep 30, 2016 66.89%
Jun 30, 2016 66.56%
Mar 31, 2016 68.71%
Dec 31, 2015 67.48%
Sep 30, 2015 67.09%
Jun 30, 2015 67.22%
Mar 31, 2015 69.54%
Dec 31, 2014 67.66%
Sep 30, 2014 67.36%
Jun 30, 2014 68.73%
Mar 31, 2014 71.28%
Dec 31, 2013 69.74%
Sep 30, 2013 71.34%
Jun 30, 2013 74.38%
Mar 31, 2013 75.50%
Dec 31, 2012 73.60%
Sep 30, 2012 74.09%
Jun 30, 2012 74.81%
Mar 31, 2012 75.80%
Dec 31, 2011 73.89%
Sep 30, 2011 75.24%
Jun 30, 2011 76.41%
Mar 31, 2011 79.10%
Dec 31, 2010 77.36%
Sep 30, 2010 77.41%
Jun 30, 2010 78.61%
Mar 31, 2010 79.51%
Dec 31, 2009 79.66%
Sep 30, 2009 80.61%